MacroGenics, Inc. (MGNX) to Release Quarterly Earnings on Tuesday

MacroGenics, Inc. (NASDAQ:MGNX) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, October 31st. Analysts expect the company to announce earnings of ($0.89) per share for the quarter.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.09). The firm had revenue of $1.70 million during the quarter, compared to the consensus estimate of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The business’s revenue for the quarter was down 97.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.12 earnings per share. On average, analysts expect MacroGenics to post $-4.24 EPS for the current fiscal year and $-4.03 EPS for the next fiscal year.

MacroGenics, Inc. (MGNX) opened at 19.45 on Monday. MacroGenics, Inc. has a one year low of $14.36 and a one year high of $31.85. The company’s market capitalization is $715.72 million. The firm has a 50-day moving average of $17.70 and a 200-day moving average of $18.15.

In other news, SVP Jon Marc Wigginton sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. Following the sale, the senior vice president now owns 40,000 shares of the company’s stock, valued at approximately $800,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.30% of the stock is currently owned by company insiders.

A number of research firms have issued reports on MGNX. Stifel Nicolaus reaffirmed a “buy” rating and issued a $34.00 price target on shares of MacroGenics in a research report on Tuesday, September 12th. Cowen and Company reaffirmed a “buy” rating on shares of MacroGenics in a research report on Friday, August 4th. ValuEngine lowered MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. BidaskClub lowered MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th. Finally, Morgan Stanley reduced their price target on MacroGenics from $22.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, August 7th. Three analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $30.30.

ILLEGAL ACTIVITY NOTICE: “MacroGenics, Inc. (MGNX) to Release Quarterly Earnings on Tuesday” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at

About MacroGenics

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Earnings History for MacroGenics (NASDAQ:MGNX)

What are top analysts saying about MacroGenics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MacroGenics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit